BIOCRYST PHARMACEUTICALS, INC.
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2016 | $23.0M | $1.6M | $22.1M |
| FY2017 | $23.0M | $83.8M | $50.3M |
| FY2018 | $30.0M | $49.2M | $26.7M |
| FY2019 | $0 | $38.3M | $114.2M |
| FY2020 | $119.7M | $-19.3M | $272.1M |
| FY2021 | $136.1M | $-107.0M | $504.4M |
| FY2022 | $231.6M | $-294.6M | $304.8M |
| FY2023 | $303.2M | $-455.5M | $110.6M |
| FY2024 | $314.9M | $-475.9M | $104.7M |
| FY2025 | $0 | $-119.2M | $89.7M |